Esophageal Cancer
1,038
198
247
443
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
123 trials with published results (12%)
Research Maturity
443 completed trials (43% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.4%
87 terminated out of 1038 trials
83.6%
-3.0% vs benchmark
8%
83 trials in Phase 3/4
28%
123 of 443 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 443 completed trials
Clinical Trials (1038)
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
Esophageal Cancer Genetics Studies
PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
IDOV-Immune for Advanced Solid Tumors
Oesophagectomy and Chest Wall and Respiratory Function
APG-2449 in Patients With Advanced Solid Tumors
Treatment Outcomes of Esophageal Cancer
DESTINY-PANTUMOUR04
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Nutrition Intervention Trials in Linxian Follow-up Study
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer